Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Appointed director

Apexigen, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 8-K Appointed a new director
Docs: "THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOF",
"BYLAWS OFPYXIS ONCOLOGY ACQUISITION CORP., A DELAWARE CORPORATION BYLAWS OFPYXIS ONCOLOGY ACQUISITION CORP. ARTICLE I"
08/22/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/18/2023 8-K Quarterly results
08/15/2023 8-K Other Events  Interactive Data
05/24/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Pyxis Oncology, Inc., Ascent Merger Sub Corp. and Apexigen, Inc",
"Form of Voting Agreement",
"Pyxis Oncology to Acquire Apexigen"
02/27/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Apexigen Announces Review of Strategic Alternatives and Restructuring"
02/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/01/2023 8-K Quarterly results
01/25/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Common Stock Purchase Warrant",
"Form of Placement Agent Warrant",
"Form of Securities Purchase Agreement",
"Form of Registration Rights Agreement",
"Apexigen Announces Approximately $2.8 Million Private Placement Financing"
08/18/2022 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "8-K/A",
"Unaudited Condensed Financial Statements of Legacy Apexigen as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 and notes thereto",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations of Legacy Apexigen for the three and six months ended June 30, 2022 and 2021",
"Unaudited Pro Forma Condensed Combined Financial Information of the Company as of and for the six months ended June 30, 2022 and for the year ended December 31, 2021"
08/04/2022 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur...
Docs: "Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company",
"Amended and Restated Warrant Agreement, by and between BCAC and Continental Stock Transfer & Trust Company, LLC",
"Apexigen, Inc. 2022 Equity Incentive Plan and forms of agreements thereunder",
"Apexigen, Inc. 2022 Employee Stock Purchase Plan and forms of agreements thereunder",
"Unaudited pro forma condensed combined financial statements for the Company as of and for the three months ended March 31, 2022 and the year ended December 31, 2021"
08/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company"
07/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the Proposed Business Combination SAN CARLOS, CA and - July 18, 2022 - On March 18, 2022 Brookline Capital Acquisition Corp. , a life-science focused Special Purpose Acquisition Company affiliated with Brookline Capital Markets, a division of Arcadia Securities, LLC , announced a proposed business combination with Apexigen, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology. The transaction values Apexigen at a $205 million net-equity basis and includes a $15 million fully committed PIPE financing that involves the sale of units consisting of one share of BCAC c..."
06/30/2022 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Even...
Docs: "Second Amended and Restated Promissory Note issued in favor of Brookline Capital Holdings, LLC",
"Brookline Capital Acquisition Corp. Confirms Receipt of Sponsor Funds to Extend Period of Time to Consummate Business Combination and for Additional Working Capital - June 30, 2022"
06/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Business Combination Agreement among Brookline Capital Acquisition Corp., Project Barolo Merger Sub, Inc., and Apexigen, Inc., a Delaware corporation",
"Amendment No. 1 to Business Combination Agreement among Brookline Capital Acquisition Corp., Project Barolo Merger Sub, Inc., and Apexigen, Inc., a Delaware corporation"
06/02/2022 8-K Quarterly results
04/26/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation",
"Brookline Capital Acquisition Corp. Announces Stockholder Approval of Extension Amendment to Complete its Business Combination with Apexigen, Inc. - April 26, 2022 - Brookline Capital Acquisition Corp. , a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase reorganization or similar business combination with one or more businesses or entities, today announced that its stockholders approved an extension of the date by which it has to consummate a business combination from May 2, 2022 ) on a monthly basis up to November 2, 2022 . BCAC requested the extension to allow more time to complete its previously announced business combination with A..."
03/18/2022 8-K Quarterly results
03/18/2022 8-K Quarterly results
12/15/2021 8-K Quarterly results
11/23/2021 8-K/A Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
06/04/2021 8-K Quarterly results
02/18/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Brookline Capital Acquisition Corp."
02/08/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Audited Balance Sheet as of February 2, 2021"
02/02/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "Underwriting Agreement, by and among the Company and Brookline Capital Holdings LLC, as representatives of the several underwriters",
"Amended and Restated Certificate of Incorporation",
"Warrant Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent",
"Letter Agreement, by and among the Company, its officers, its directors and the Sponsor",
"Investment Management Trust Agreement, by and between the Company and Continental Stock Transfer & Trust Company, as trustee",
"Registration Rights Agreement, between the Registrant and certain security holders",
"Administrative Support Agreement, by and between the Company and Brookline Capital Markets, a division of Arcadia Securities, LLC",
"Unit Subscription Agreement, by and between the Company and the Sponsor",
"Samuel P. Wertheimer Brookline Capital Acquisition Corp.",
"Samuel P. Wertheimer Brookline Capital Acquisition Corp."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy